GSGang Shi

Gang Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gang Shi has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Fang Liu

    Department of Pathology, Shengjing Hospital of China Medical University

    3 shared publications
  • Jiaxun Tian

    Department of Laboratory, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, China

    3 shared publications
  • Rui Zhang

    Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, China

    3 shared publications
  • Yun Qiao

    Department of Pathology, Shengjing Hospital of China Medical University

    3 shared publications
  • Jianfeng Zhao

    Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China

    2 shared publications
  • Wei Sun

    2 shared publications

Latest Publications

  • Universal screening for Lynch syndrome in operated colorectal cancer by immunohistochemistry: a cohort of patients in Liaoning province, China

    by Guangyue Zhao, Guoqing Xiang, Xiaoru Hu, Yun Qiao, Shiyang Ma, Ye Tian, Xiaozuo Gao, Fang Liu, Xiaohan Li, Gang Shi

    Objective: Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome worldwide. Due to the decreasing family size in Liaoning province. The Bethesda and Amsterdam II criteria have lower sensitivity and specificity and are not suitable for the local population. Immunohistochemistry screening for mutations in DNA mismatch repair (MMR) in newly diagnosed colorectal cancer can improve the detection rate of LS. Methods: All newly diagnosed colorectal cancer patients who underwent surgery between January 2018 and June 2020 at Cancer Hospital of China Medical University and Shengjing Hospital of China Medical University from Liaoning China were included retrospectively, and the ratio of universal LS screening by immunohistochemistry, MMR protein deficiency (dMMR) ratio, MLH1 loss, MSH2 loss, MSH6 loss, and PMS2 loss was analyzed. The clinicopathological characteristics of patients with pMMR and dMMR were analyzed. Results: A total of 7019 colorectal cancer patients underwent surgery and 4802 (68.41%) patients were screened by immunohistochemistry for MMR, 258 (5.37%) cases were reported to have a loss of MMR expression. In the dMMR group, a higher number of patients were under 50 years old, more tumors were located at the right colon, less patients have lymph node metastasis, more tumors were stage II, and histological types of mucinous carcinoma or signet ring carcinoma were more common, compared with the pMMR group. Only 2.71% dMMR patients meet Amsterdam criteria II, 2.71% of patients meet Revised Bethesda guidelines, and 17.83% meet Chinese LS criteria. Twenty-five dMMR patients were confirmed by next-generation sequencing and five families were confirmed as Lynch family. Conclusion: These data imply that universal screening for LS by immunohistochemistry may be effective in Liaoning province.


  • LINC00261 inhibits progression of pancreatic cancer by down-regulating miR-23a-3p

    by Xin Wang, Xiaozhuo Gao, Jiaxun Tian, Rui Zhang, Yun Qiao, Xiangdong Hua, Gang Shi


  • Open Access

    TSPAN1 promotes human pancreatic cancer cells proliferation by modulating CDK1 via Akt

    by Xin Wang, Xiaozhuo Gao, Jiaxun Tian, Rui Zhang, Yun Qiao, Xiangdong Hua, Gang Shi, Zuo Xiao Gao

    Background: To explore the potential therapeutic target to treat pancreatic cancers, Tspan1 was detected in human pancreatic cancer tissue and human pancreatic ductal adenocarcinoma cells and functional role of Tspan1 on proliferation was explored and the mechanism was investigated. Materials and Methods: Tspan1 in PCC tissue and PDAC cell lines was measured by qRT-PCR and Western blot. Tspan1 was knock-downed and over-expressed in cells via transfection with Tspan1-siRNA and pLNCX-TSPAN1-cDNA, cell survival, proliferation and cell cycle were measured with MTT, Alamar blue and Flow Cytometry assay. The mRNA and protein expression were assessed by qRT-PCR and Western blotting. The expression of PI3K, Akt and p-Akt were detected, and CDK1 siRNA and specific inhibitor of Akt were used to explore the mechanism of TSPAN1 promoting PDAC cells proliferation. Results: Tspan1 expression in PCC tissue and PDAC cells was increased. Transfection of siRNA targeting Tspan1 in BxPC3 and PNAC-1 cells obviously decreased cell proliferation and down-regulated CDK1 expression. Consistently, both cell proliferation and CDK1 expression in BxPC3 and PNAC-1 cells were up-regulated with pLNCX-TSPAN1-cDNA transfection. Cell cycle analysis showed that after knockdown of Tspan1 the G2/M phase ratio was increased to cause mitosis arrest, and TSPAN1 overexpression caused cell cycle transition from G2 to M phase to promote cell proliferation. And these were dependent on the modulation of CDK1 expression via Akt. Conclusion: Tspan1 up-regulates CDK1 expression via activating Akt to promote human PCC cell proliferation and silencing of Tspan1 may be a potential therapeutic target to treat pancreatic cancers.

  • Open Access

    Silencing Tspan1 inhibits migration and invasion, and induces the apoptosis of human pancreatic cancer cells

    by Jiaxun Tian, Rui Zhang, Haiyan Piao, Xiaoxi Li, Weiwei Sheng, Jianping Zhou, Ming Dong, Xiaobo Zhang, Xiaofei Yan, Wen Shang, et al.

    Pancreatic cancer (PCC) is one of the most dangerous types of tumor as it is very difficult to treat and its 5‑year survival rate is <6%. To date, there have been no effective therapeutic strategies to treat PCC, thus, novel effective therapeutic methods are required. Tetraspanin 1 (Tspan1) is a novel member of the tetraspanins superfamily and is highly expressed in a variety of types of cancer, including gastric, hepatocellular and colonic carcinomas. However, the detailed functional role of Tspan1 in pancreatic cancer cells is still unclear and further investigation is required to uncover its therapeutic potential for the treatment of different tumor types. The purpose of the present study was to investigate the expression of Tspan1 in human PCC tissues and cells, and explore the effect of Tspan1 silencing on invasion, migration, cell survival and apoptosis in human PCC to clarify its function. Expression levels of Tspan1 were analyzed in human pancreatic cancer tissues and the cell lines Capan‑2 and SW1990 using immunohistochemistry staining, reverse transcription‑quantitative polymerase chain reaction and western blotting. The effects of downregulation of Tspan1 expression on cell survival, apoptosis, invasion and migration were investigated viaTspan1‑small interfering (si)RNA transfection into human PCC cell lines. The results indicated that Tspan1 expression was increased in human PCC tissues compared with the adjacent normal pancreatic tissues. Tspan1 was highly expressed in the human PCC cell lines Capan‑2 and SW1990 when compared with the normal pancreatic cell line HPC‑Y5. In addition, transfection with siRNA‑targeting Tspan1 significantly reduced cell migration and invasion, and increased the cell apoptosis of Capan‑2 and SW1990. The present findings highlighted the important role of Tspan1 in human PCC cell migration, invasion and apoptosis. Thus, Tspan1 RNA interference may serve as a potential therapeutic strategy to treat human PCC.


  • Open Access

    Cell Recognition Molecule L1 Regulates Cell Surface Glycosylation to Modulate Cell Survival and Migration

    by Gang Shi, Yue Du, Yali Li, Yue An, Zhenwei He, Yingwei Lin, Rui Zhang, Xiaofei Yan, Jianfeng Zhao, Shihua Yang, et al.

    Background: Cell recognition molecule L1 (L1) plays an important role in cancer cell differentiation, proliferation, migration and survival, but its mechanism remains unclear.


    • 1 October 2014
      • Vol. 52  (10) , 781-6

    [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].

    by Gang Shi, Ming Dong, Weiwei Sheng, Jianping Zhou, Dongyang Yu, Wei Sun

    To explore the clinicopathological significance and relationship of Tspan 1 and Integrin α6 expression in pancreatic ductal adenocarcinoma (PDAC) tissue and pancreatic cancer cell lines. Immunohistochemistry was used to detect the expression of Tspan 1 and Integrin α6 in 95 paraffin-embedded PDAC specimens and 55 adjacent non-cancerous pancreatic tissues which were collected from May 2004 to January 2013.Western blot and quantitative real-time polymerase chain reaction (qRT-PCR) were used to detected the protein and mRNA expression in 16 paired fresh PDAC specimens of the pancreas and adjacent non-cancerous pancreatic tissues and 6 different pancreatic cancer cell lines.χ(2) test, Spearman-rank correlation analysis, Kaplan-Meier method and multivariate Cox regression analysis were used to analyze the data. Tspan 1 and Integrin α6 were significantly over-expressed in PDAC than in adjacent non-cancerous pancreatic tissues (χ(2) = 7.429, P < 0.05; χ(2) = 15.1, P < 0.01). Lymph node metastasis, TNM stage and post-operation recurrence were positively correlated with the expression of Tspan 1 (χ(2) = 6.688, P < 0.01; χ(2) = 13.055, P < 0.01; χ(2) = 6.116, P < 0.05) . TNM stage was positively correlated with the expression of Integrin α6 (χ(2) = 8.896, P < 0.05) . Tspan 1 was correlated with Integrin α6 (r = 0.223, P < 0.05) . The expressions of Tspan 1 and Integrin α6 were negatively correlated with survival time (χ(2) = 5.263, P < 0.05;χ(2) = 10.124, P < 0.01) . Multivariate analysis revealed that Tspan 1 and Integrin α6 expressions were independent prognostic factors in PDAC patients (χ(2) = 6.152, P < 0.05; χ(2) = 9.479, P < 0.01). Western blot (t = 2.278, P < 0.05; t = 3.153, P < 0.05) and qRT-PCR (t = 2.439, P < 0.05; t = 3.258, P < 0.05) showed that Tspan 1 and Integrin α6 expressions were higher in PDAC tissues than in adjacent non-cancerous pancreatic. Tspan 1 and Integrin α6 were expressed in all six pancreatic cancer cell lines.In SW1990 which derived from metastasis PDAC, Tspan 1 and Integrin α6 expressions were higher than the cell lines from primary tumor. Tspan 1 and Integrin α6 expression can up-regulate the invasion and metastasis of PDAC and may be used to predict the prognosis of PDAC.


  • Open Access

    Effects of gastrokinetic agents on human sphincter of Oddi motility

    by Gang Shi, Shuo-Dong Wu, Bo Liu, Wei Sun, Xiao-Bo Zhang, Jing Kong

    目的: 观察在消化间期, 常规剂量的多潘利酮、莫沙必利、替加色罗对Oddi括约肌(sphincter of Oddi, SO)运动功能的影响. 方法: 胆道探查术后留有T型管患者32例, 进行前瞻性病例对照研究, 采用抽签法随机分为潘利酮组、莫沙必利组、替加色罗组, 测量用药前后的十二指肠压(DP)、SO基础压(SOBP)、收缩波幅(SOCA)、收缩频率(SOF)、收缩间期(SOD)及胆总管压(CBDP). 结果: 舌下含服多潘利酮后SOBP明显降低(10.30±4.99 vs 6.40±3.66, Pvs 68.67±41.02, Pvs 6.00±5.74; 83.44±46.16 vs 52.48±44.19, 均P结论: 常规剂量的多潘利酮、莫沙必利对SO运动功能具有抑制作用, 引起Oddi松弛; 常规剂量的替加色罗可能对SO运动功能无明显影响.